Grace Therapeutics (GRCE) Director Kavuru Vimal Receives Award

What Happened
Kavuru Vimal, a director of Grace Therapeutics (GRCE), was granted an award of 12,200 derivative securities on 2026-09-17. The Form 4 lists the acquisition price as $0.00 and reports the transaction as a grant/award (derivative). This is a compensation-related award rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-09-17; filing date: 2026-09-21. The filing was submitted four days after the transaction (Form 4s are typically due within two business days).
• Security: 12,200 derivative shares (grant/award). Price per share reported as $0.00; no cash value is reported on the Form 4.
• Shares owned after transaction: Not disclosed in the provided filing details.
• Footnote: 50% of the award vests on the grant date; the remaining 50% vests in substantially equal monthly installments over 12 months, subject to the reporting person’s continued service as of each vesting date.
• No indication in the filing that shares were sold immediately or that a 10b5-1 trading plan was used.

Context
This is a compensation grant (derivative award), commonly used to compensate executives and board members. Such awards are not the same as an outright market purchase and do not by themselves signal buying or selling intent. The vesting schedule means only half of the award was immediately vested; the remainder vests over the following year contingent on continued service.